Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.

Corynn KasapAdila IzgutdinaBonell Patiño-EscobarAmrik KangNikhil ChilakapatiNaomi AkagiHaley JohnsonTasfia RashidJuwita WernerAbhilash BarpandaHuimin GengYu-Hsiu T LinSham RampersaudDaniel Gil-AlósAmin SobhDaphné Dupéré-RicherGianina WicaksonoK M Kawehi KeliiRadhika DalalEmilio RamosAnjanaa VijayanarayananFernando SalangsangPaul PhojanakongJuan Antonio Camara SerranoOns ZakraouiIsa TariqVeronica SteriMala ShanmugamLawrence H BoiseTanja KortemmeElliot StieglitzJonathan D LichtWilliam J KarlonBenjamin G BarwickArun P Wiita

Published in: bioRxiv : the preprint server for biology (2024)

Structure-optimized CD27-based CAR-T cells targeting CD70 are a promising therapeutic option for high-risk multiple myeloma patients who are most likely to relapse on current BCMA-targeting cellular therapies.

Keyphrases

multiple myeloma
induced apoptosis
cell cycle arrest
cancer therapy
ejection fraction
newly diagnosed
nk cells
endoplasmic reticulum stress
prognostic factors
oxidative stress
cell death
drug delivery